PharmAla Biotech Logo 800 x 422.png
PharmAla Announces Private Placement and Concurrent Debt Settlement
April 10, 2024 16:30 ET | PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
PharmAla Biotech Logo 800 x 422.png
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET | PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
PharmAla Biotech Logo 800 x 422.png
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024 08:55 ET | PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Biotech Logo 800 x 422.png
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
November 09, 2023 08:55 ET | PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
PharmAla Biotech Logo 800 x 422.png
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET | PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments